NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report-Reference-Cited by-同舟云学术

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Published:2014-10-09 Issue:15 Volume:124 Page:2400-2407
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ostronoff Fabiana¹²,Othus Megan³⁴,Gerbing Robert B.⁵,Loken Michael R.⁶,Raimondi Susana C.⁷,Hirsch Betsy A.⁸,Lange Beverly J.⁹,Petersdorf Stephen¹⁰,Radich Jerald¹²,Appelbaum Frederick R.¹²,Gamis Alan S.⁵¹¹,Alonzo Todd A.⁵¹²,Meshinchi Soheil¹⁵

Affiliation:

1. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA;

2. University of Washington, Seattle, WA;

3. Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA;

4. SWOG Statistical Center, Seattle, WA;

5. Children's Oncology Group, Arcadia, CA;

6. Hematologics, Inc., Seattle, WA;

7. St. Jude Children's Research Hospital, Pathology Division, Memphis, TN;

8. University of Minnesota Medical Center-Fairview, Minneapolis, MN;

9. Children's Hospital of Philadelphia, Department of Pediatrics, Division of Oncology, Philadelphia, PA;

10. Seattle Genetics, Inc., Seattle, WA;

11. Children's Mercy Hospitals and Clinics, Kansas City, MO; and

12. University of Southern California, Los Angeles, CA

Abstract

Key Points Coexpression of NUP98/NSD1 and FLT3/ITD in AML is associated with very low complete remission rates and poor survival. It is the interaction between NUP98/NSD1 and FLT3/ITD that determines poor outcome in NUP98/NSD1-associated AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/15/2400/1381152/2400.pdf

Reference42 articles.

1. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.;Mrózek;Curr Opin Hematol,2007

2. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.;Schlenk;N Engl J Med,2008

3. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.;Slovak;Blood,2000

4. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).;Byrd;Blood,2002

5. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.;Grimwade;Blood,2010

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core‐binding factor;Pediatric Blood & Cancer;2023-12-06

2. The future of HOXA-expressing leukemias: Menin inhibitor response and resistance;Current Opinion in Hematology;2023-11-23

3. Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10

4. Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China;Bone Marrow Transplantation;2023-09-20

5. Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia—Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022;Cancers;2023-09-14